OptiMedica donates photocoagulator to ORBIS

Article

OptiMedica Corp has donated a PASCAL photocoagulator to non-profit organization ORBIS International, under a new partnership between the two companies.

OptiMedica Corp has donated a PASCAL photocoagulator to non-profit organization ORBIS International, under a new partnership between the two organizations.

The PASCAL photocoagulator, which decreases the duration and frequency of photocoagulation while increasing the safety, comfort and efficiency of the procedure, will be used onboard ORBIS's Flying Eye Hospital to train doctors in the developing world to treat retinal disorders, particularly diabetic retinopathy.

The technology was first used by ORBIS on the Flying Eye Hospital's first visit to Laos, a country with 25 ophthalmologists and 30,000 blind among the population of six million. The visit concluded on January 30th and was attended by an engineer from OptiMedica.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.